- Details
- Michael Morris joins Alicia Morgans in a discussion on the evolution of research in prostate cancer. They speak about the transition from relying on prognostic models to using biomarkers and discussing patient selection criteria, which has led to the explosive growth in the field, with new standards of care and questions arising every year. They also discuss the growth of international collaborati...
|
- Details
- Alicia Morgans is joined by Andrea Necchi in a conversation on the CheckMate 274 trial, the use of biomarkers in the adjuvant setting, and how they can be used to understand the effect of nivolumab. Necchi and colleagues performed an exploratory analysis to assess the association between disease-free survival (DFS) and biomarkers (continuous scale) and estimate treatment-effect hazard ratios for b...
|
- Details
- In a detailed discussion between Pedro Barata and Camillo Porta, they dissect the findings from the update of the CLEAR study. The study explores the effectiveness of lenvatinib and pembrolizumab versus sunitinib in treating advanced renal cell carcinoma patients. The results revealed significantly higher medium progression-free survival and overall survival rates for the lenvatinib/pembrolizumab...
|
- Details
- In this discussion, Pedro Barata and Nizar Tannir focus on the PIVOT-09 Phase III trial. They delve into the potential and challenges of the experimental combination treatment, bempegaldesleukin (BEMPEG) plus nivolumab, which showed promising initial results but was terminated due to disappointing trial outcomes. Despite this, Dr. Tannir remains optimistic about the Interleukin 2 (IL-2) pathway, p...
|
- Details
- In this discussion, Michael Morris and Alicia Morgans discuss a post hoc analysis of the VISION Trial aimed at assessing earlier maturing time-to-event endpoints. Earlier time-to-event endpoints than overall survival (OS) will allow more timely regulatory approval and overall accelerated drug development. Morris and colleagues aimed to estimate correlations between time-to-event endpoints such as...
|
- Details
- Alicia Morgans and Guru Sonpavde discuss the results of Cohort K of the EV-103 trial presented at the 2022 European Society for Medical Oncology (ESMO) Annual Congress. There remains a critical need for effective and tolerable first-line treatment options in locally advanced or metastatic urothelial cancer. In second and later-line settings, both EV and pembrolizumab have independently shown an ov...
|
- Details
- Pedro Barata is joined by Maxime Meylan to discuss a key ancillary analysis of the phase II BIONIKK trial aimed at understanding immune markers predictive of the efficacy of immune checkpoint inhibition as first-line therapy in metastatic clear cell renal cell carcinoma (mccRCC). This analysis demonstrates that the number of tertiary lymphoid structures and ki67+PD1+ density likely predict the eff...
|
- Details
- Rana McKay and Alicia Morgans discuss the CYCLONE 3 trial in progress in high-risk metastatic hormone-sensitive prostate cancer (mHSPC). Recent data from the ARASENS trial shows a survival benefit for treatment intensification with ADT + docetaxel + a novel hormonal agent, triplet therapy, vs ADT + docetaxel in selected patients. Yet, there is a significant medical need to expand therapeutic optio...
|
- Details
- Nicholas James joins Alicia Morgans in a discussion of the first results of the novel BladderPath trial examining the role of magnetic resonance imaging (MRI) for bladder cancer staging. BladderPath is a randomized comparison of the time from the initial diagnosis to “correct” treatment among patients with possible muscle-invasive bladder cancer who receive staging with MRI, compared to TURBT. Nic...
|
- Details
- Fred Saad joins Alicia Morgans in a discussion focusing on the biomarker analysis and updated results from the Phase III PROpel trial of abiraterone and olaparib vs abiraterone and placebo as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). This updated analysis provides more detail on patients with HRR mutations in the PROpel trial. In this biomarker a...
|
